Yuyu Pharma, Inc. (000227.KS)
KRW 9750.0
(-0.41%)
KRW 9750.0
(-0.41%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 47.25 Billion KRW | -12.34% |
| 2022 | 53.9 Billion KRW | 22.14% |
| 2021 | 44.13 Billion KRW | 13.17% |
| 2020 | 38.99 Billion KRW | 1.2% |
| 2019 | 38.53 Billion KRW | 9.14% |
| 2018 | 35.3 Billion KRW | 33.66% |
| 2017 | 26.41 Billion KRW | -10.86% |
| 2016 | 29.63 Billion KRW | 1.29% |
| 2015 | 29.25 Billion KRW | -1.58% |
| 2014 | 29.72 Billion KRW | -2.9% |
| 2013 | 30.61 Billion KRW | -3.22% |
| 2012 | 31.63 Billion KRW | 1.61% |
| 2011 | 31.13 Billion KRW | 5.55% |
| 2010 | 29.49 Billion KRW | 12.28% |
| 2009 | 26.27 Billion KRW | -19.59% |
| 2008 | 32.67 Billion KRW | -12.95% |
| 2007 | 37.52 Billion KRW | 9.83% |
| 2006 | 34.16 Billion KRW | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 8.34 Billion KRW | -4.76% |
| 2024 Q1 | 8.87 Billion KRW | -18.73% |
| 2023 Q1 | 11.84 Billion KRW | -15.92% |
| 2023 Q2 | 12.92 Billion KRW | 9.11% |
| 2023 Q4 | 10.91 Billion KRW | 185.87% |
| 2023 FY | 47.25 Billion KRW | -12.34% |
| 2023 Q3 | -12.71 Billion KRW | -198.39% |
| 2022 Q2 | 13.55 Billion KRW | 0.87% |
| 2022 FY | 53.9 Billion KRW | 22.14% |
| 2022 Q4 | 14.08 Billion KRW | 9.89% |
| 2022 Q1 | 13.44 Billion KRW | 16.21% |
| 2022 Q3 | 12.81 Billion KRW | -5.46% |
| 2021 FY | 44.13 Billion KRW | 13.17% |
| 2021 Q1 | 10.7 Billion KRW | 0.6% |
| 2021 Q2 | 10.92 Billion KRW | 2.01% |
| 2021 Q3 | 10.93 Billion KRW | 0.08% |
| 2021 Q4 | 11.56 Billion KRW | 5.8% |
| 2020 Q1 | 8.14 Billion KRW | -26.34% |
| 2020 Q3 | 10.87 Billion KRW | 16.52% |
| 2020 Q4 | 10.64 Billion KRW | -2.11% |
| 2020 FY | 38.99 Billion KRW | 1.2% |
| 2020 Q2 | 9.33 Billion KRW | 14.61% |
| 2019 Q1 | 9.56 Billion KRW | 2.55% |
| 2019 Q2 | 8.88 Billion KRW | -7.13% |
| 2019 FY | 38.53 Billion KRW | 9.14% |
| 2019 Q4 | 11.05 Billion KRW | 22.52% |
| 2019 Q3 | 9.02 Billion KRW | 1.54% |
| 2018 Q1 | 7.98 Billion KRW | 0.0% |
| 2018 FY | 35.3 Billion KRW | 33.66% |
| 2018 Q2 | 8.88 Billion KRW | 11.31% |
| 2018 Q4 | 9.33 Billion KRW | 2.53% |
| 2018 Q3 | 9.1 Billion KRW | 2.38% |
| 2017 Q3 | 8.32 Billion KRW | 1.84% |
| 2017 Q1 | 8.04 Billion KRW | 8.11% |
| 2017 FY | 26.41 Billion KRW | -10.86% |
| 2017 Q2 | 8.17 Billion KRW | 1.62% |
| 2016 Q4 | 7.44 Billion KRW | 18.71% |
| 2016 Q1 | 5.57 Billion KRW | -34.22% |
| 2016 FY | 29.63 Billion KRW | 1.29% |
| 2016 Q3 | 6.26 Billion KRW | -20.46% |
| 2016 Q2 | 7.88 Billion KRW | 41.31% |
| 2015 FY | 29.25 Billion KRW | -1.58% |
| 2015 Q4 | 8.47 Billion KRW | 12.45% |
| 2015 Q3 | 7.53 Billion KRW | -1.63% |
| 2015 Q2 | 7.66 Billion KRW | 5.36% |
| 2015 Q1 | 7.27 Billion KRW | -4.96% |
| 2014 Q3 | 7.38 Billion KRW | -0.35% |
| 2014 FY | 29.72 Billion KRW | -2.9% |
| 2014 Q4 | 7.65 Billion KRW | 3.62% |
| 2014 Q1 | 7.61 Billion KRW | 1.43% |
| 2014 Q2 | 7.41 Billion KRW | -2.65% |
| 2013 Q4 | 7.5 Billion KRW | 0.2% |
| 2013 Q1 | 7.54 Billion KRW | 0.19% |
| 2013 Q2 | 8.1 Billion KRW | 7.39% |
| 2013 Q3 | 7.49 Billion KRW | -7.54% |
| 2013 FY | 30.61 Billion KRW | -3.22% |
| 2012 Q3 | 8.12 Billion KRW | -3.6% |
| 2012 Q4 | 7.53 Billion KRW | -7.36% |
| 2012 FY | 31.63 Billion KRW | 1.61% |
| 2012 Q2 | 8.43 Billion KRW | 0.0% |
| 2012 Q1 | - KRW | -100.0% |
| 2011 Q3 | 7.28 Billion KRW | -2.55% |
| 2011 Q2 | 7.47 Billion KRW | -2.03% |
| 2011 FY | 31.13 Billion KRW | 5.55% |
| 2011 Q1 | 7.62 Billion KRW | 5.94% |
| 2011 Q4 | 8.08 Billion KRW | 11.07% |
| 2010 Q4 | 7.2 Billion KRW | -9.93% |
| 2010 Q3 | 7.99 Billion KRW | 20.55% |
| 2010 Q2 | 6.63 Billion KRW | 5.75% |
| 2010 Q1 | 6.27 Billion KRW | 8.64% |
| 2010 FY | 29.49 Billion KRW | 12.28% |
| 2009 Q4 | 5.77 Billion KRW | -16.63% |
| 2009 Q3 | 6.92 Billion KRW | -5.14% |
| 2009 Q1 | 6.86 Billion KRW | -11.7% |
| 2009 Q2 | 7.3 Billion KRW | 6.38% |
| 2009 FY | 26.27 Billion KRW | -19.59% |
| 2008 Q1 | 9.97 Billion KRW | 4.02% |
| 2008 FY | 32.67 Billion KRW | -12.95% |
| 2008 Q4 | 7.77 Billion KRW | -8.67% |
| 2008 Q3 | 8.5 Billion KRW | -10.67% |
| 2008 Q2 | 9.52 Billion KRW | -4.55% |
| 2007 FY | 37.52 Billion KRW | 9.83% |
| 2007 Q2 | 8.7 Billion KRW | 0.0% |
| 2007 Q3 | 9.24 Billion KRW | 6.22% |
| 2007 Q4 | 9.59 Billion KRW | 3.75% |
| 2006 FY | 34.16 Billion KRW | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Dong-A Socio Holdings Co., Ltd. | 297.99 Billion KRW | 84.143% |
| Ildong Holdings Co., Ltd. | 278.43 Billion KRW | 83.029% |
| HANDOK Inc. | 153.76 Billion KRW | 69.269% |
| Kukje Pharma Co., Ltd. | 69.21 Billion KRW | 31.727% |
| Yuhan Corporation | 489.94 Billion KRW | 90.355% |
| Dong-A ST Co., Ltd. | 306.95 Billion KRW | 84.606% |
| SAMSUNG PHARM. Co., LTD. | 41.78 Billion KRW | -13.076% |
| Hanmi Pharm. Co., Ltd. | 610.97 Billion KRW | 92.266% |
| Hanall Biopharma Co.,Ltd | 71.98 Billion KRW | 34.354% |
| Ilyang Pharmaceutical Co.,Ltd | 174.14 Billion KRW | 72.866% |
| Dong Sung Bio Pharm.Co.,Ltd. | 40.05 Billion KRW | -17.978% |
| MYUNGMOON Pharm co.,Ltd | 93.55 Billion KRW | 49.489% |
| Hana Pharm Co., Ltd. | 114.72 Billion KRW | 58.811% |
| Yuyu Pharma, Inc. | 47.25 Billion KRW | 0.0% |
| Ilsung Pharmaceuticals Co., Ltd. | 42.47 Billion KRW | -11.26% |
| REYON Pharmaceutical Co., Ltd. | 75.04 Billion KRW | 37.036% |
| Aprogen pharmaceuticals,Inc. | 58.64 Billion KRW | 19.423% |
| JW Holdings Corporation | 301.25 Billion KRW | 84.314% |
| Ildong Pharmaceutical Co., Ltd. | 260.95 Billion KRW | 81.892% |
| Chong Kun Dang Pharmaceutical Corp. | 408.65 Billion KRW | 88.437% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | 80.221% |
| Shin Poong Pharm.Co.,Ltd. | 127.66 Billion KRW | 62.987% |
| Hyundai Pharmaceutical Co., Ltd. | 68.31 Billion KRW | 30.825% |
| Samil Pharmaceutical Co.,Ltd | 65.75 Billion KRW | 28.132% |
| Jeil Pharmaceutical Co.,Ltd | 174.92 Billion KRW | 72.986% |
| Yuyu Pharma, Inc. | 47.25 Billion KRW | 0.0% |
| Kwang Dong Pharmaceutical Co., Ltd. | 249.12 Billion KRW | 81.032% |
| Daewoong pharmaceutical Co.,Ltd | 560.43 Billion KRW | 91.568% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | 80.221% |
| Yuhan Corporation | 489.94 Billion KRW | 90.355% |
| Jeil Pharma Holdings Inc | 193.66 Billion KRW | 75.6% |
| Yungjin Pharm. Co., Ltd. | 69.46 Billion KRW | 31.978% |
| Suheung Co., Ltd. | 56.03 Billion KRW | 15.666% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | 80.221% |
| Samjin Pharmaceuticals Co., Ltd. | 126.39 Billion KRW | 62.613% |
| Korea United Pharm Inc. | 118.21 Billion KRW | 60.027% |
| CKD Bio Corp. | 25.19 Billion KRW | -87.547% |
| Daewon Pharmaceutical Co., Ltd. | 221.99 Billion KRW | 78.714% |
| Dongwha Pharm.Co.,Ltd | 165.11 Billion KRW | 71.381% |
| Whan In Pharm Co.,Ltd. | 66.41 Billion KRW | 28.853% |
| Shin Poong Pharm.Co.,Ltd. | 127.66 Billion KRW | 62.987% |
| Chong Kun Dang Holdings Corp. | 350.71 Billion KRW | 86.526% |
| Boryung Corporation | 285.16 Billion KRW | 83.429% |
| Bukwang Pharmaceutical Co., Ltd. | 87.54 Billion KRW | 46.021% |
| Ilyang Pharmaceutical Co.,Ltd | 174.14 Billion KRW | 72.866% |
| JW Lifescience Corporation | 20.26 Billion KRW | -133.219% |